Facts and Figures
The year Pharm&Access was founded
in Team and growing
population covered in Region
countries operating
Gender Balanced Team
Orphan company as providing consultancy and business development in the Region
This Code of Conduct sets out our values as well as basic standards and principles of behavior, adherence to which are vitally important to both the reputation and success of our Company.
We do our best to bring unique medicine to each and every patient with rare disease.
CARE and TREAT, which means:
C – Communication
A – Activeness
R – Reliability
E – Efficiency
T – Trust
R – Responsibility
E – Ethics
A – Accompaniment
T – Teamwork
Pharm&Access company is successful in business development in right manner with high standard of ethics and compliance. We are a partner Pharm&Access in Central Asia and Caucasus countries based in Almaty, Kazakhstan that provides full support to international pharmaceutical companies who need support in orphan/rare disease in Central Asia and Caucasus countries. 1 single point of contact gives you the opportunity to sell your products through us to more than 8 countries (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan, Azerbaijan, Georgia and Armenia) with more than 80 million people population.
Pharm&Access company is successful in sales and marketing of orphan diseases direction in these countries. We are a well-respected and trusted company and we will do our outmost best to sell your products in our part of Region. We have 1 mission: to exceed your expectations of the cooperation with us!
Apart from our sales capabilities, we can handle the distribution, market access (price, reimbursement, hospital protocols) and the registration, even successful lead patient named sales, expanded access programs for each rare disease patients in our Region.
8 countries, 8 official languages. 93 million population. Pharmaceutical market size of the region is about 6 billion USD. Kazakhstan, Uzbekistan and Azerbaijan – reimbursement of orphan drugs at place. Georgia and Armenia – insurance healthcare system. Reimbursement of some orphan drugs. Turkmenistan, Tajikistan and Kyrgyzstan – out of pocket market
Learn more further on www.orphankz.com
In 2019, we calculate that the total pharmaceutical sales in Kazakhstan amounted to KZT563bn (USD1.47bn), equating to 0.8% of GDP and 26% of health expenditure. Due to the rapid evolution of Kazakhstan's pharmaceutical and healthcare markets, we maintain a bullish outlook for pharmaceutical sales. In 2020, we anticipate drug sales to increase by 12.5% in local currency terms and 4.9% in US dollar terms, reaching KZT633bn (USD1.54bn). Over the next five years, we forecast that the market will expand at a local currency compound annual growth rate (CAGR) of 10.9% and 12.3% in US dollar terms, reaching a market value of KZT943bn (USD2.62bn) in 2024. By 2029, we anticipate the market to be valued at KZT1.49tn (USD4.26bn), reflecting a 10-year CAGR of 10.2% in local currency term and 11.2% in US dollar terms. This places it as one of the fastest growing pharmaceutical markets in the European region. However, pharmaceutical spending per capita is low even by regional standards, at just USD79 in 2019 (Fitch Kazakhstan Pharmaceuticals & Healthcare Report 2020).
Contact Us
The Uzbek pharmaceutical market reached a value of UZS5.7trn (USD645mn) in 2019. Our pharmaceutical expenditure forecast sees pharmaceutical spending increasing steadily over the forecast period, reaching UZS9.6trn (USD786mn) in 2024. This translates to a five-year compound annual growth rate (CAGR) of 11.0% in local currency terms and 4.0% in US dollar terms. Over a 10-year period, we forecast the market to grow at a CAGR of 9.1% in local currency terms and 4.0% in US dollar terms to a value of UZS13.6trn (USD957.0mn). Pharmaceutical sales as a percentage of total healthcare expenditure are expected to moderate from 22.0% in 2019 to 16.2% in 2024. Per capita spending on medicines is expected to increase from USD20 in 2019 to USD22 in 2024 (Fitch Uzbekistan Pharmaceuticals & Healthcare Report – 2020)
Contact Us
Azerbaijan's pharmaceutical market is forecast to grow from AZN859mn (USD505mn) in 2019 to AZN949mn (USD558mn) in 2020, increasing by 10.5% y-o-y in local currency terms. By 2024, the market will be valued AZN1.4bn (USD702mn), posting a five-year local currency compound annual growth rate (CAGR) of 9.5% (6.8% in US dollar terms) (Fitch Azerbaijan Pharmaceuticals & Healthcare Report – 2020)
Contact Us
Georgia's pharmaceutical market, worth some GEL1.27bn (USD451mn) in 2019, is expected to post an 8.8% y-o-y local currency growth in 2020 to reach GEL1.38bn (USD432mn). We have maintained our expectation for the local currency y-o-y growth, despite the coronavirus situation, given that most of the additional expenses will be realised in the healthcare services domain.
By 2024, the market is forecast to reach GEL1.75bn (USD625mn), growing at a five-year local currency compound annual growth rate (CAGR) of 6.6% (+6.8% in US dollar terms). Over the longer 2019-2029 forecast period, we respectively forecast CAGRs of 5.8% in local currency terms and 5.9% in US dollar terms, with the market reaching a value of GEL2.24bn (USD799mn) (Fitch Georgia Pharmaceuticals & Healthcare Report – 2020)
Contact Us
Growth in Kyrgyzstan's and other countries pharmaceutical market is volatile, given much dependency on private spending to procure medicines. In 2020, the market is forecast to grow by 11.8% y-o-y in local currency terms (but stagnate in US dollar terms) to KGS19.5bn (USD250mn), from KGS17.5bn (USD250mn) in 2019. On a per capita basis, Kyrgyzstan spends USD39 on medicine in 2019, with this figure falling below both the mean and median averages (around USD55) among the Commonwealth of Independent States (CIS) countries. Pharmaceuticals represent a major share of the overall healthcare spending, at 42%, with this figure expected to grow further in the coming years, despite the expansion of services.
The rest countries are shown the same indicators and growth (Fitch Pharmaceuticals & Healthcare Report – 2020). The rest countries indicated will be provided upon request.
Contact Us
